CHAPTER 4 204 32. Tromp J, Tay WT, Ouwerkerk W, Teng T-HK, Yap J, MacDonald MR, et al. Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLOS Medicine 2018;15:e1002541. doi:10.1371/journal.pmed.1002541. 33. Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215–225. doi:10.1093/eurheartj/ehi115. 34. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351–1357. doi:10.1056/NEJM200105033441802. 35. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R, Ferdinand K, et al. Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. New England Journal of Medicine 2004;351:2049–2057. doi:10.1056/NEJMoa042934. 36. Ziaeian B, Fonarow GC, Heidenreich PA. Clinical Effectiveness of Hydralazine–Isosorbide Dinitrate in African-American Patients With Heart Failure. JACC: Heart Failure 2017;5:632–639. doi:10.1016/j.jchf.2017.04.008. 37. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. The Lancet 2020;396:819–829. doi:10.1016/S0140-6736(20)31824-9. 38. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 2016;18:613–625. doi:10.1002/ejhf.566. 39. Lam CSP, Anand I, Zhang S, Shimizu W, Narasimhan C, Park SW, et al. Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry. Eur J Heart Fail 2013;15:928–936. doi:10.1093/eurjhf/hft045. 40. Dokainish H, Teo K, Zhu J, Roy A, AlHabib KF, ElSayed A, et al. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. The Lancet Global Health 2017;5:e665–e672. doi:10.1016/S2214-109X(17)30196-1. 41. Greene SJ, DeVore AD, Sheng S, Fonarow GC, Butler J, Califf RM, et al. Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF. JACC Heart Fail 2019;7:980–992. doi:10.1016/j.jchf.2019.07.011. 42. Michos ED, Reddy TK, Gulati M, Brewer LC, Bond RM, Velarde GP, et al. Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statement. Am J Prev Cardiol 2021;8:100250. doi:10.1016/j.ajpc.2021.100250. 43. Commissioner O of the. Collection of Race and Ethnicity Data in Clinical Trials. US Food and Drug Administration 2019. https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/collection-race-and-ethnicity-data-clinical-trials (accessed November 4, 2022). 44. Nagaraj S, Nai-Peng T, Chiu-Wan N, Kiong-Hock L, Pala J. Counting Ethnicity in Malaysia: The Complexity of Measuring Diversity. In: Simon P, Piché V, Gagnon AA, editors. Social Statistics and Ethnic Diversity: Cross-National Perspectives in Classifications and Identity Politics, Cham: Springer International Publishing; 2015, p. 143–173. doi:10.1007/978-3-319-20095-8_8. 45. U.S. Food & Drug Administration. Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products guidance for industry. Maryland: U.S Food & Drug Administration; 2019. 46. Patel HC, Hayward C, Dungu JN, Papadopoulou S, Saidmeerasah A, Ray R, et al. Assessing the Eligibility Criteria in Phase III Randomized Controlled Trials of Drug Therapy in Heart Failure With Preserved Ejection Fraction: The Critical Play-Off Between a “Pure” Patient Phenotype and the Generalizability of Trial Findings. J Card Fail 2017;23:517–524. doi:10.1016/j.cardfail.2017.04.006. 47. O’Connor CM, Psotka MA, Fiuzat M, Lindenfeld J, Abraham WT, Bristow MR, et al. Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. J Am Coll Cardiol 2018;71:443–453. doi:10.1016/j.jacc.2017.11.048.
RkJQdWJsaXNoZXIy MjY0ODMw